Australia markets closed

InspireMD, Inc. (NSPR)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.3701+0.0501 (+2.16%)
At close: 04:00PM EDT
2.2910 -0.08 (-3.34%)
After hours: 05:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.3200
Open2.2950
Bid2.2300 x 1800
Ask2.5400 x 900
Day's range2.2200 - 2.4500
52-week range0.9600 - 3.8500
Volume59,827
Avg. volume23,927
Market cap55.594M
Beta (5Y monthly)0.85
PE ratio (TTM)N/A
EPS (TTM)-0.8200
Earnings date14 May 2024 - 20 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.50
  • GlobeNewswire

    InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

    TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig,

  • Insider Monkey

    InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript

    InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript March 6, 2024 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.16, expectations were $-0.2. InspireMD, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to InspireMD Fourth Quarter and […]

  • GlobeNewswire

    InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

    - Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CGuard Prime - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company’s C-GUARDIANS II clinical trial of its SwitchGuard™ NPS for Transcarotid Artery Revascularization (TCAR),